Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis
S Alhumaid, A Al Mutair, Z Al Alawi, N Alhmeed… - Tropical medicine and …, 2020 - mdpi.com
(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
Y Wang, D Zhao, X Chen, X Liu… - Influenza and other …, 2023 - Wiley Online Library
Background The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter …
X Han, D Gao, C Li, X Yuan, J Cui, W Zhao, F Xie… - BMC Infectious …, 2024 - Springer
Background and aim Two oral antivirals (Nirmatrelvir-ritonavir and Azvudine) are widely
used in China practice during the Omicron wave of the pandemic. However, little evidence …
used in China practice during the Omicron wave of the pandemic. However, little evidence …
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
S Congdon, Z Narrowe, N Yone, J Gunn, Y Deng… - Scientific reports, 2023 - nature.com
We conducted a retrospective cohort study to assess whether treatment with
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …
Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a critical appraisal of literature
AK Singh, R Singh, B Saboo, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
Background & aims Several observational studies have recently reported the outcomes of
non-insulin anti-diabetic agents (ADA) in patients with T2DM and coronavirus disease 2019 …
non-insulin anti-diabetic agents (ADA) in patients with T2DM and coronavirus disease 2019 …
Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID‐19 patients: a prospective observational study conducted on Pakistani population
QH Qureshi, T Ashraf, K Rehman… - Journal of Medical …, 2021 - Wiley Online Library
We aimed to investigate the interventions of remdesivir in both diabetic and nondiabetic
individuals who were suffering from a severe infection of novel coronavirus disease (COVID …
individuals who were suffering from a severe infection of novel coronavirus disease (COVID …
SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study
GE Edelstein, J Boucau, R Uddin, C Marino… - Annals of Internal …, 2023 - acpjournals.org
Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among US Veterans: A Target Trial Emulation
GN Ioannou, K Berry, N Rajeevan, Y Li… - Annals of internal …, 2023 - acpjournals.org
Background: COVID-19 has been linked to the development of many post–COVID-19
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …
Effect of antidiabetic therapy on clinical outcomes of COVID-19 patients with type 2 diabetes: a systematic review and meta-analysis
K Zhan, L Weng, L Qi, L Wang, H Lin… - Annals of …, 2023 - journals.sagepub.com
Background: No study has yet systematically evaluated the effect of antidiabetic therapy on
clinical outcomes of COVID-19 patients with type 2 diabetes (T2D). Objective: We aimed to …
clinical outcomes of COVID-19 patients with type 2 diabetes (T2D). Objective: We aimed to …